SB 324: Health care coverage: endometriosis.
- Session Year: 2023-2024
- House: Senate
- Latest Version Date: 2023-03-30
Current Status:
Failed
(2023-09-01: September 1 hearing: Held in committee and under submission.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
(1)Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law generally authorizes a health care service plan or health insurer to use prior authorization and other utilization review functions, under which a licensed physician or a licensed health care professional who is competent to evaluate specific clinical issues may approve, modify, delay, or deny requests for health care services based on medical necessity.
This bill would prohibit a health care service plan contract or health insurance policy issued, amended, delivered, or renewed on or after January 1, 2024, from requiring prior authorization or other utilization review for laparoscopic surgery for endometriosis. any clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
(2)Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Existing law sets forth a schedule of benefits under the Medi-Cal program.
This bill would add laparoscopic surgery for endometriosis any clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines, as a covered benefit under Medi-Cal without prior authorization or other utilization review.
(3)The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(1)Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law generally authorizes a health care service plan or health insurer to use prior authorization and other utilization review functions, under which a licensed physician or a licensed health care professional who is competent to evaluate specific clinical issues may approve, modify, delay, or deny requests for health care services based on medical necessity.
This bill would prohibit a health care service plan contract or health insurance policy issued, amended, delivered, or renewed on or after January 1, 2024, from requiring prior authorization or other utilization review for laparoscopic surgery for endometriosis. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
(2)Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Existing law sets forth a schedule of benefits under the Medi-Cal program.
This bill would add laparoscopic surgery for endometriosis as a covered benefit under Medi-Cal without prior authorization or other utilization review.
The(3)The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law generally authorizes a health care service plan or health insurer to use prior authorization and other utilization review functions, under which a licensed physician or a licensed health care professional who is competent to evaluate specific clinical issues may approve, modify, delay, or deny requests for health care services based on medical necessity.
This bill would prohibit a health care service plan contract or health insurance policy issued, amended, delivered, or renewed on or after January 1, 2024, from requiring prior authorization or other utilization review for laparoscopic surgery for endometriosis. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
A health care service plan contract issued, amended, delivered, or renewed on or after January 1, 2024, shall not require prior authorization or other utilization review for laparoscopic surgery for endometriosis. any clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines.
SEC. 2.Section 10123.186 is added to the Insurance Code, to read:10123.186.A health insurance policy issued, amended, delivered, or renewed on or after January 1, 2024, shall not require prior authorization or other utilization review for laparoscopic surgery for endometriosis. any clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines.
SEC. 3.Section 14132.04 is added to the Welfare and Institutions Code, to read:14132.04.Laparoscopic surgery for endometriosis Clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines, shall be a covered Medi-Cal benefit without prior authorization or other utilization review.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
A health care service plan contract issued, amended, delivered, or renewed on or after January 1, 2024, shall not require prior authorization or other utilization review for laparoscopic surgery for endometriosis.
SEC. 2.Section 10123.186 is added to the Insurance Code, to read:10123.186.A health insurance policy issued, amended, delivered, or renewed on or after January 1, 2024, shall not require prior authorization or other utilization review for laparoscopic surgery for endometriosis.
SEC. 3.Section 14132.04 is added to the Welfare and Institutions Code, to read:14132.04.Laparoscopic surgery for endometriosis shall be a covered Medi-Cal benefit without prior authorization or other utilization review.
SEC. 3.SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
A health care service plan contract issued, amended, delivered, or renewed on or after January 1, 2024, shall not require prior authorization or other utilization review for laparoscopic surgery for endometriosis.
SEC. 2.Section 10123.186 is added to the Insurance Code, to read:10123.186.A health insurance policy issued, amended, delivered, or renewed on or after January 1, 2024, shall not require prior authorization or other utilization review for laparoscopic surgery for endometriosis.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Sep 1, 2023 | September 1 hearing: Held in committee and under submission. |
| Aug 23, 2023 | August 23 set for first hearing. Placed on suspense file. |
| Jun 28, 2023 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 12. Noes 2.) (June 27). Re-referred to Com. on APPR. |
| Jun 1, 2023 | Referred to Com. on HEALTH. |
| May 25, 2023 | In Assembly. Read first time. Held at Desk. |
| May 24, 2023 | Read third time. Passed. (Ayes 31. Noes 7. Page 1270.) Ordered to the Assembly. |
| May 18, 2023 | Read second time. Ordered to third reading. |
| May 18, 2023 | From committee: Do pass. (Ayes 5. Noes 1. Page 1165.) (May 18). |
| May 12, 2023 | Set for hearing May 18. |
| Apr 24, 2023 | April 24 hearing: Placed on APPR suspense file. |
| Apr 18, 2023 | Set for hearing April 24. |
| Apr 13, 2023 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 10. Noes 1. Page 710.) (April 12). Re-referred to Com. on APPR. |
| Mar 30, 2023 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Mar 28, 2023 | Set for hearing April 12. |
| Mar 9, 2023 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Feb 15, 2023 | Referred to Com. on HEALTH. |
| Feb 7, 2023 | From printer. May be acted upon on or after March 9. |
| Feb 6, 2023 | Introduced. Read first time. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jun 27, 2023 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
|
| May 24, 2023 | Senate 3rd Reading SB324 Limón | Senate Floor |
Passed |
|
| May 18, 2023 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 24, 2023 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 12, 2023 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| American College Of Obstetricians And Gynecologists District Ix | ** Support | |
| AmericaS Health Insurance Plans | ** Against | |
| Association Of California Life & Health Insurance Companies | ** Against | |
| California Association Of Health Plans | ** Against | |
| California Life Sciences | ** Support | |
| California Medical Association | ** Support |
Date of Hearing: August 23, 2023
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Chris Holden, Chair
SBPCA Bill Id:SB 324
Author:(Limón) – As Amended Ver:March 30, 2023
Policy Committee: | Health | Vote: | 12 - 2 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill prohibits a health care service plan contract (health plan), health insurance policy (insurance policy), and the Medi-Cal program from requiring prior authorization (PA) or other utilization review (UR) for clinically indicated treatment for endometriosis.
FISCAL EFFECT:
- Minor and absorbable costs to the Department of Managed Health Care (DMHC).
- The California Department of Insurance (CDI) estimates costs of $6,000 in fiscal year (FY) 2023-24 (Insurance Fund).
- Ongoing costs of an unknown amount, likely exceeding $150,000, in the Medi-Cal program due to possibly greater utilization of endometriosis treatment services (General Fund and federal funds).
- The California Public Employees Retirement System anticipates costs of an unknown but likely nominal amount (Public Employees Health Care Fund).
COMMENTS:
- Purpose. According to the author:
An estimated one in ten women in the United States between the ages of 25 and 40 are affected by endometriosis. A 2020 PubMed study noted that 5.2% of patients reported being misdiagnosed with another physical health (95.1%), a mental health problem (49.5%), or both before they received an endometriosis diagnosis. Hence, on average, women in the United States will suffer from endometriosis for 10 years before receiving a proper diagnosis. This bill prohibits health plans and insurance policies from requiring prior authorization or other utilization review for any clinically indicated treatment for endometriosis. SB 324 will expedite the process for women to receive a proper diagnosis of endometriosis and secure treatment to improve fertility and quality of life.
- PA. PA is a decision by a health plan or insurer that a health service, treatment plan, prescription drug, or durable medical equipment is medically necessary. The health plan or insurer may require PA for certain services before an individual receives them, except in an emergency. Health plans and insurers are subject to various requirements in California, including an obligation to file policies and procedures that describe UR functions used to authorize, modify, or deny health care services. Additionally, existing law requires these policies and procedures to ensure decisions based on the medical necessity of proposed health services are consistent with criteria or guidelines that are supported by clinical principles and processes.
State law requires DMHC to conduct a routine medical survey of each licensed full service and specialty health plan at least once every three years. DMHC may also perform an investigative medical survey as often as deemed necessary by DMHC's director. The medical survey is a comprehensive evaluation of the plan's compliance with the law with regard to quality assurance, grievances and appeals (enrollee complaints), access and availability, utilization management (including PA), and overall performance in meeting enrollees' health care needs.
It is not clear that PA or UR have an effect on access to care or quality of care, health outcomes, or costs for endometriosis treatment. Although there is anecdotal evidence of problems with PA, there is limited data available related to how Californians are affected by PA policies. In May 2023, the chairs of the Assembly and Senate Health Committees requested the California Health Benefits Review Program (CHBRP) prepare a report to help the Legislature understand how California health plans and health insurers are using PA to control and manage covered health care services, drugs, devices, durable medical equipment and pharmaceutical products. The request also asked CHBRP to identify evidence of PA delaying or otherwise impacting patient outcomes for any particular conditions.
- Related Legislation.
- AB 931 (Irwin) prohibits a health plan or insurance policy that provides coverage for physical therapy from imposing PA for the initial 12 treatment visits for a new episode of care for physical therapy. AB 931 is pending in Senate Appropriations Committee.
- AB 1288 (Reyes) prohibits a health plan and a health insurer from subjecting to PA a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder, as specified. AB 1288 is pending in Senate Appropriations Committee.
- SB 238 (Wiener) requires a health plan or insurer that modifies, delays, or denies a mental health or substance use disorder service based on medical necessity, to automatically submit the decision to the Independent Medical Review System, for an enrollee or insured up to 26 years of age. SB 238 is pending in this committee.
- SB 598 (Skinner) prohibits a health plan or health insurer from requiring a contracted health professional to complete or obtain PA for any covered health care services if the plan or insurer approved or would have approved not less than 90% of the PA requests from this provider in the most recent one-year contracted period. SB 598 also requires a plan or insurer to have a process for monitoring PA approval, modification, appeal, and denial rates to identify services, items, and supplies that are regularly approved, and to discontinue PA on those services, items, and supplies that are approved 95% of the time. SB 598 is pending in this committee.
- Prior Legislation.
- SB 535 (Limon), Chapter 605, Statutes of 2021, prohibited health plans and insurers from requiring PA for biomarker testing for advanced or metastatic stage 3 or 4 cancer, and cancer progression or recurrence.
- AB 250 (Pan), of the 2021-22 Legislative Session, was similar to SB 598 and was held in this committee.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: June 27, 2023
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
SBPCA Bill Id:SB 324
Author:(Limón) – As Amended Ver:March 30, 2023
SENATE VOTE: 31-7
SUBJECT: Health care coverage: endometriosis.
SUMMARY: Prohibits a health plan contract or health insurance policy issued, amended, delivered, or renewed on or after January 1, 2024, from requiring prior authorization or other utilization review (UR) for any clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines. Requires Medi-Cal coverage of clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines, without prior authorization or other UR.
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975; the California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services to administer the Medi-Cal program. [Health and Safety Code (HSC) §1340, et seq., Insurance Code (INS) §106, et seq., and Welfare and Institutions Code §14000, et seq.]
- Establishes as California's essential health benefits (EHBs) benchmark under the Patient Protection and Affordable Care Act (ACA), the Kaiser Small Group Health Maintenance Organization, existing California health insurance mandates, and the 10 ACA mandated benefits, including prescription drug coverage. [HSC §1367.005 and INS §10112.27]
- Defines “basic health care services” as all of the following:
- Physician services, including consultation and referral;
- Hospital inpatient services and ambulatory care services;
- Diagnostic laboratory and therapeutic radiologic services;
- Home health services;
- Preventive health services;
- Emergency health care services, including ambulance and ambulance transport services and out-of-area coverage. Basic health care services includes ambulance and ambulance transport services provided through the 911 emergency response system; and,
- Hospice care, as specified. [HSC §1345]
- Requires the criteria or guidelines used by health plans and insurers, or any entities with which plans or insurers contract for UR or utilization management (UM) functions, to determine whether to authorize, modify, or deny health care services to:
- Be developed with involvement from actively practicing health care providers;
- Be consistent with sound clinical principles and processes;
- Be evaluated, and updated if necessary, at least annually;
- If used as the basis of a decision to modify, delay, or deny services in a specified case under review, be disclosed to the provider and the enrollee or insured in that specified case; and,
- Be available to the public upon request. [HSC §1363.5 and INS §10123.135]
- Requires reviews, for purposes of Independent Medical Review (IMR), to determine whether the disputed health care service was medically necessary based on the specific medical needs of the enrollee or insured and any of the following:
- Peer-reviewed scientific and medical evidence regarding the effectiveness of the disputed service;
- Nationally recognized professional standards;
- Expert opinion;
- Generally accepted standards of medical practice; or,
- Treatments that are likely to provide a benefit to a patient for conditions for which other treatments are not clinically efficacious. [HSC §1374.33 and INS §10169.3]
FISCAL EFFECT: According to the Senate Appropriations Committee:
- Unknown, ongoing cost pressures in the Medi-Cal program (General Fund and federal funds) due to potentially greater utilization of endometriosis treatment services as a result of prohibiting prior authorization or other utilization review;
- The CDI estimates $6,000 (Insurance Fund) for state administration in 2023-24; and,
- The DMHC estimates minor and absorbable costs for state administration.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, an estimated one in ten women in the United States between the ages of 25 and 40 are affected by endometriosis. A 2020 PubMed study noted that 5.2% of patients reported being misdiagnosed with another physical health (95.1%), a mental health problem (49.5%), or both before they received an endometriosis diagnosis. The author states that hence, on average, women in the United States will suffer from endometriosis for 10 years before receiving a proper diagnosis. This bill prohibits health plans and insurance policies from requiring prior authorization or other UR for any clinically indicated treatment for endometriosis. The author concludes that this bill will expedite the process for women to receive a proper diagnosis of endometriosis and secure treatment to improve fertility and quality of life.
- BACKGROUND.
- Prior Authorization. Prior authorization is a decision by a health plan or insurer that a health care service, treatment plan, prescription drug, or durable medical equipment is medically necessary. The health plan or insurer may require preauthorization for certain services before an individual receives them, except in an emergency.
Health plans and insurers are subject to various requirements in California, as stated in existing law above, including an obligation to file policies and procedures that describe UR or UM functions, used to authorize, modify, or deny health care services under the benefits provided by the health plan. Additionally, existing law requires these policies and procedures to ensure that decisions based on the medical necessity of proposed health care services are consistent with criteria or guidelines that are supported by clinical principles and processes.
Furthermore, California law requires DMHC to conduct a routine medical survey of each licensed full service and specialty health plan at least once every three years. DMHC may also perform an investigative medical survey as often as deemed necessary by DMHC's Director. The medical survey is a comprehensive evaluation of the plan's compliance with the law in the following health plan program areas:- Quality Assurance;
- Grievances and Appeals (enrollee complaints);
- Access and Availability;
- UM (referrals and authorizations); and,
- Overall plan performance in meeting enrollees' health care needs.
- Existing consumer protections. In California, consumers have many health care rights, including the right to know why a plan denies a service or treatment, and the right to file a grievance if the consumer disagrees. Health plans are required to have grievance and appeals systems to assist consumers in resolving these issues. A health plan’s grievance program informs consumers of their full grievance and appeal rights and the protections afforded to them under the law, including the right to pursue an IMR or file a complaint with the DMHC if they are dissatisfied with their health plan’s decision. A robust grievance program also allows health plans to track and trend grievances for the purpose of uncovering systemic problems, thereby providing the opportunity for quality improvement.
- Endometriosis. According to the University of California, San Francisco Endometriosis Center, endometriosis is a condition in which tissue from the lining of the uterus, also called endometrium, grows outside the uterus. This growth can occur on the ovaries, fallopian tubes, intestines or other areas in the pelvis. This tissue acts just like the endometrium in accumulating blood during a woman’s monthly menses, but has no place to shed the blood at the end of the cycle. The accumulation of tissue and blood can cause inflammation and scarring, which can lead to other conditions like pelvic pain and infertility. Blood trapped in the ovaries may develop into benign cysts called endometriomas. Between 25 and 50% of infertile women are estimated to have endometriosis. Endometriosis affects more than one million women in the United States and at this time, the exact cause of the condition is unknown.
- Prior Authorization. Prior authorization is a decision by a health plan or insurer that a health care service, treatment plan, prescription drug, or durable medical equipment is medically necessary. The health plan or insurer may require preauthorization for certain services before an individual receives them, except in an emergency.
The author provided information that according to the U.S. Department of Health and Human Services, National Institutes of Health, endometriosis happens when tissue similar to the lining of the uterus grows outside the uterus. It may affect more than 11% of American women between the ages of 15 and 44, and is common among women in their 30s and 40s. Endometriosis can make it difficult to get pregnant. Endometriosis is diagnosed by pelvic exam, imaging tests, or Laparoscopy (a type of surgery where tissue samples are taken or growths can be seen). Medication can be prescribed to help with the pain caused by endometriosis. Since endometriosis symptoms are nonspecific and can also be present in other diseases diagnosis can be delayed. A 2020 study published in Advances in Therapy found that patients with endometriosis who had longer diagnostic delays had more symptoms and higher utilization and costs compared to those diagnosed earlier. Pre-diagnosis, all-cause healthcare costs were significantly higher among patients with longer diagnostic delays, averaging $21,489, $30,030, and $34,460 among patients with a short, intermediate, and long delay, respectively.
- SUPPORT. The California Medical Association writes that treatment for endometriosis depends on the extent of the disease, your symptoms, and whether you want to have children, as determined by the treating physician. Endometriosis may be treated with medication, surgery, or both. When pain is the primary problem, medication usually is tried first prior to surgery. Regardless of treatment type, a provider and a patient should have access to treatments that are clinically indicated and evidenced-based that best treat that individual’s condition without unnecessary prior authorization requirements, which may delay care.
- OPPOSITION. The California Association of Health Plans (CAHP), the Association of California Life and Health Insurance Companies (ACLHIC), and America’s Health Insurance Plans (AHIP) write to oppose a list of 20 health insurance mandate bills indicating that health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. All ACA-compliant plans provide a robust package of EHBs in the large group, small business, and individual markets (both on and off the Exchange). In the individual market, the ACA sought to preserve the balance between comprehensive coverage and affordability by requiring states to bear the cost for new mandates that exceed the EHB package. The Centers for Medicaid and Medicare Services recently affirmed that states are still responsible for defraying the cost of new mandates.
- RELATED LEGISLATION.
- SB 598 (Skinner) prohibits a health plan or health insurer from requiring a contracted health professional to complete or obtain a prior authorization for any covered health care services if the plan or insurer approved or would have approved not less than 90% of the prior authorization requests they submitted in the most recent one-year contracted period. Sets standards for this exemption and its denial, rescission, and appeal. Authorizes a plan or insurer to evaluate the continuation of an exemption not more than once every 12 months, and authorizes a plan or insurer to rescind an exemption only at the end of the 12-month period and only if specified criteria are met. Requires a plan or insurer to provide an electronic prior authorization process. Requires a plan or insurer to have a process for annually monitoring prior authorization approval, modification, appeal, and denial rates to identify services, items, and supplies that are regularly approved, and to discontinue prior authorization on those services, items, and supplies that are approved 95% of the time. SB 598 is pending in Assembly Health Committee.
- AB 931 (Irwin) prohibits a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides coverage for physical therapy from imposing prior authorization for the initial 12 treatment visits for a new episode of care for physical therapy. AB 931 is pending in Senate Health Committee.
- AB 1288 (Reyes) prohibits a medical service plan and a health insurer from subjecting a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder that is prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder to prior authorization. AB 1288 is pending in Senate Health Committee.
- AB 496 (Limon) requires a health plan contract or health insurance policy issued, amended, or renewed on or after July 1, 2024, to provide coverage for medically necessary biomarker testing, as prescribed, including whole genome sequencing, for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee’s or insured’s disease or condition to guide treatment decisions if the test is supported by medical and scientific evidence, as prescribed. Applies these provisions relating to biomarker testing to the Medi-Cal program, including Medi-Cal managed care plans, as specified. AB 496 is pending in Assembly Health Committee.
- PREVIOUS LEGISLATION.
- AB 250 (Pan) of 2021 was similar to SB 598 and would have prohibited a health plan or health insurer from requiring a contracted health professional to complete or obtain a prior authorization for any health care services if the plan or insurer approved or would have approved not less than 90% of the prior authorization requests they submitted in the most recent one-year contracted period. AB 250 was held in Assembly Appropriations Committee.
- SB 535 (Limon), Chapter 605, Statutes of 2021, prohibits health plans and insurers from requiring prior authorization for biomarker testing for advanced or metastatic stage 3 or 4 cancer, and cancer progression or recurrence.
REGISTERED SUPPORT / OPPOSITION:
Support
American College of Obstetricians and Gynecologists District IX
California Life Sciences
California Medical Association
Opposition
America’s Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 324 |
THIRD READING
Bill No: SB 324
Author: Limón (D)
Amended: 3/30/23
Vote: 21
SENATE HEALTH COMMITTEE: 10-1, 4/12/23
AYES: Eggman, Glazer, Gonzalez, Hurtado, Limón, Menjivar, Roth, Rubio, Wahab, Wiener
NOES: Nguyen
NO VOTE RECORDED: Grove
SENATE APPROPRIATIONS COMMITTEE: 5-1, 5/18/23
AYES: Portantino, Ashby, Bradford, Wahab, Wiener
NOES: Jones
NO VOTE RECORDED: Seyarto
SUBJECT: Health care coverage: endometriosis
SOURCE: Author
DIGEST:
This bill prohibits health plans, insurers, and the Medi-Cal program from requiring prior authorization or other utilization review for any clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Requires the criteria or guidelines used by health plans and insurers, or any entities with which plans or insurers contract for utilization review or utilization management functions, to determine whether to authorize, modify, or deny health care services to:
- Be developed with involvement from actively practicing health care providers;
- Be consistent with sound clinical principles and processes;
- Be evaluated, and updated if necessary, at least annually;
- If used as the basis of a decision to modify, delay, or deny services in a specified case under review, be disclosed to the provider and the enrollee or insured in that specified case; and,
- Be available to the public upon request. [HSC §1363.5 and INS §10123.135]
- Requires health plans and insurers and any contracted entity that performs utilization review or utilization management functions, retrospectively, or concurrently, based on medical necessity requests to comply with specified requirements. [HSC §1367.01 and INS §10123.135]
- Requires, under federal law, a group health plan and a health insurance issuer offering group or individual health insurance coverage to implement an effective appeals process for appeals of coverage determinations and claims, including an internal claims appeal process with notices in a culturally and linguistically appropriate manner, of available internal and external appeals process. Establishes processes for internal and external reviews. [42 USC §300gg-19]
This bill:
- Prohibits health plan contracts and health insurance policies issued, amended, delivered, or renewed on or after January 1, 2024 from requiring prior authorization or other utilization review for any clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines.
- Makes clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines a covered Medi-Cal benefit without prior authorization or other utilization review.
Comments
Author’s statement. According to the author, an estimated one in ten women in the United States between the ages of 25 and 40 are affected by endometriosis. A 2020 PubMed study noted that 5.2% of patients reported being misdiagnosed with another physical health (95.1%), a mental health problem (49.5%), or both before they received an endometriosis diagnosis. Hence, on average, women in the United States will suffer from endometriosis for 10 years before receiving a proper diagnosis. This bill will expedite the process for women to receive a proper diagnosis for endometriosis and secure treatment to improve fertility and quality of life.
Endometriosis. According to the U.S. Department of Health and Human Services, National Institutes of Health, endometriosis happens when tissue similar to the lining of the uterus grows outside the uterus. It may affect more than 11% of American women between the ages of 15 and 44, and is common among women in their 30s and 40s. Endometriosis can make it difficult to get pregnant. Endometriosis is diagnosed by pelvic exam, imaging tests, or Laparoscopy (a type of surgery where tissue samples are taken or growths can be seen). Medication can be prescribed to help with the pain caused by endometriosis. Since endometriosis symptoms are nonspecific and can also be present in other diseases diagnosis can be delayed. A 2020 study published in Advances in Therapy found that patients with endometriosis who had longer diagnostic delays had more symptoms and higher utilization and costs compared to those diagnosed earlier. Pre-diagnosis, all-cause healthcare costs were significantly higher among patients with longer diagnostic delays, averaging $21,489, $30,030, and $34,460 among patients with a short, intermediate, and long delay, respectively.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee analysis:
- Unknown, ongoing cost pressures in the Medi-Cal program (General Fund and federal funds) due to potentially greater utilization of endometriosis treatment services as a result of prohibiting prior authorization or other utilization review.
- The CDI estimates $6,000 (Insurance Fund) for state administration in 2023-24.
- The DMHC estimates minor and absorbable costs for state administration.
SUPPORT: (Verified 5/18/23)
American College of Obstetricians and Gynecologists District IX
California Life Sciences
OPPOSITION: (Verified 5/18/23)
America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
ARGUMENTS IN SUPPORT: California Life Sciences writes that endometriosis is a chronic inflammatory disease in which uterine tissue grows in the pelvic region causing severe pain, nausea, fatigue, and even infertility. It affects approximately 10% of reproductive-age women worldwide and domestically. While the exact causes of endometriosis are still an active area of research and no cure has yet to be developed, its symptoms can be effectively managed through early diagnosis and treatments including analgesics, non-steroidal anti-inflammatory drugs, hormonal interventions, and surgical removal of endometriosis growths. Laparoscopic surgery is often preferred among other surgical interventions due to its minimal-invasiveness, minimization of scar tissue, and faster post-operative recovery time. By requiring health plans and insurers to cover laparoscopic surgery for endometriosis, this bill will improve the quality of life for the approximately one million Californians who live with this condition. The American College of OB/GYN’s District IX writes that treatment for endometriosis depends on the extent of the disease, symptoms, and whether a patient wants to have children, as determined by the treating physician. Endometriosis may be treated with medication, surgery, or both. When pain is the primary problem, medication usually is tried first prior to surgery. Regardless of treatment type, a provider and a patient should have access to what is clinically indicated and evidenced based to best treat that individual’s condition, without unnecessary prior authorization requirements which may delay care.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write in opposition to this along with 23 other health insurance mandate bills. These bills include mandates for health plans and insurers to cover specific services, as well as bills that eliminate cost sharing and limit utilization management, which have similar cost impacts as coverage mandates. Moreover, they will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. State mandates increase costs of coverage – especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates. Benefit mandates that do not promote evidence-based medicine can lead to lower quality care, over- or misutilization of services, and higher costs for treatments that may be ineffective, less safe, or higher cost than other, new or trusted services. California is rightly focused on achieving both universal coverage and cost containment at a time when the national conversation has shifted toward lower costs through less comprehensive options. The California Chamber of Commerce writes employer-based health care coverage is usually one of the largest expenses a business experiences and, while this bill is well intentioned, it will unintentionally exacerbate health care affordability issues.
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
5/20/23 12:44:30
**** END ****
SENATE COMMITTEE ON
Senator Anthony Portantino, Chair
2023 - 2024 Regular Session
SB 324 (Limón) - Health care coverage: endometriosis
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
SB 324 would prohibit health plans, insurers, and the Medi-Cal program from requiring prior authorization or other utilization review for any clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines.
Fiscal Impact:
- Unknown, ongoing cost pressures in the Medi-Cal program (General Fund and federal funds) due to potentially greater utilization of endometriosis treatment services as a result of prohibiting prior authorization or other utilization review.
- The Department of Insurance estimates $6,000 (Insurance Fund) for state administration in 2023-24.
- The Department of Managed Health Care estimates minor and absorbable costs for state administration.
Background:
The Department of Managed Health Care (DMHC) regulates health plans under the Knox-Keene Act and the California Department of Insurance (CDI) regulates health insurance. Current law establishes the Medi-Cal program, administered by the Department of Health Care Services (DHCS), under which low-income individuals are eligible for medical coverage.
Prior authorization is a form of utilization review or utilization management used by health plans and insurers to determine whether to authorize, modify, or deny health care services. Utilization review can occur prospectively, retrospectively, or concurrently and a plan or insurer can approve, modify, delay or deny in whole or in part a request based on its medical necessity. California law requires written policies and procedures that are consistent with criteria or guidelines that are supported by clinical principles and processes. These policies and procedures must be filed with regulators, and disclosed, upon request, to providers, plans and enrollees or insureds. There are timelines in the law for plans and insurers to respond to requests once any requested medical information that is reasonably necessary to make the determination is provided. California also has a standardized form for prior authorization submissions. If a health plan or insurer fails to respond to the prior authorization request within 72 hours for nonurgent requests, and within 24 hours if exigent circumstances exist, upon the receipt of a completed form, the request is deemed granted.
According to the U.S. Department of Health and Human Services, National Institutes of Health, endometriosis happens when tissue similar to the lining of the uterus grows outside the uterus. It may affect more than 11% of American women between the ages of 15 and 44, and is common among women in their 30s and 40s. Endometriosis can make it difficult to get pregnant. Endometriosis is diagnosed by pelvic exam, imaging tests, or laparoscopy (a type of surgery where tissue samples are taken or growths can be seen). Medication can be prescribed to help with the pain caused by endometriosis.
Proposed Law:
Specific provisions of the bill would:
- Prohibit health plan contracts and health insurance policies issued, amended, delivered, or renewed on or after January 1, 2024 from requiring prior authorization or other utilization review for any clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines.
- Make clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines, a covered Medi-Cal benefit without prior authorization or other utilization review.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Susan Talamantes Eggman, Chair
BILL NO: SB 324
AUTHOR: | Limón | ||
VERSION: | March 30, 2023 | ||
HEARING DATE: | April 12, 2023 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Health care coverage: endometriosis
SUMMARY:
- Prohibits health plans, insurers, and the Medi-Cal program from requiring prior authorization or other utilization review for any clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Requires the criteria or guidelines used by health plans and insurers, or any entities with which plans or insurers contract for utilization review or utilization management functions, to determine whether to authorize, modify, or deny health care services to:
- Be developed with involvement from actively practicing health care providers;
- Be consistent with sound clinical principles and processes;
- Be evaluated, and updated if necessary, at least annually;
- If used as the basis of a decision to modify, delay, or deny services in a specified case under review, be disclosed to the provider and the enrollee or insured in that specified case; and,
- Be available to the public upon request. [HSC §1363.5 and INS §10123.135]
- Requires health plans and insurers and any contracted entity that performs utilization review or utilization management functions, retrospectively, or concurrently, based on medical necessity requests to comply with specified requirements. [HSC §1367.01 and INS §10123.135]
- Prohibits any individual, other than a licensed physician or a licensed health care professional who is competent to evaluate the specific clinical issues involved in the health care services requested by the provider, from denying or modifying requests for authorization of health care services for an enrollee or insured for reasons of medical necessity. Requires the decision to be communicated to the provider within 24 hours of the decision, and the enrollee (in writing) within two business days of the decision. In the case of concurrent review, prohibits discontinuance of care until the treating provider has been notified and has agreed to a care plan that is appropriate for the medical needs of the patient. [HSC §1367.01 and INS §10123.135]
- Requires, if a health plan or insurer that provides coverage for prescription drugs fails to respond to a prior authorization or step therapy exception request, as specified, within 72 hours for nonurgent requests, and within 24 hours if exigent circumstances exist, upon the receipt of a completed form, the request to be deemed granted. [HSC §1367.241 and INS §10123.191]
- Establishes an independent medical review (IMR) process, under which enrollee and insured grievances involving a disputed health care service are eligible for review. Defines “disputed health care service” as any health care service eligible for coverage and payment under the contract that has been denied, modified, or delayed by a decision of the plan, or contracting provider, in whole or in part due to a finding that the service is not medically necessary. [HSC §1374.30 and INS §10169]
- Establishes a process for expeditiously reviewing IMR requests related to imminent and serious threat to the enrollee. [HSC §1374.31 and INS §10169.1]
- Requires every health plan to establish and maintain a grievance system approved by DMHC under which enrollees may submit their grievances and complaints to the plan. Permits enrollees to submit those grievances to DMHC after undergoing the plan’s internal process for at least 30 days, unless the case involves imminent and serious threat, severe pain, potential loss of life, limb, or major bodily function, cancellations, rescissions, or the nonrenewal of a contract or any other case where DMHC determines early review is warranted. [HSC §1368]
- Requires, under federal law, a group health plan and a health insurance issuer offering group or individual health insurance coverage to implement an effective appeals process for appeals of coverage determinations and claims, including an internal claims appeal process with notices in a culturally and linguistically appropriate manner, of available internal and external appeals process. Establishes processes for internal and external reviews. [42 USC §300gg-19]
This bill:
- Prohibits health plan contracts and health insurance policies issued, amended, delivered, or renewed on or after January 1, 2024 from requiring prior authorization or other utilization review for any clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines.
- Makes clinically indicated treatment for endometriosis, as determined by the treating physician and consistent with nationally recognized evidence-based clinical guidelines a covered Medi-Cal benefit without prior authorization or other utilization review.
FISCAL EFFECT:
This bill has not been analyzed by a fiscal committee.
COMMENTS:
- Author’s statement. According to the author, an estimated one in ten women in the United States between the ages of 25 and 40 are affected by endometriosis. A 2020 PubMed study noted that 5.2% of patients reported being misdiagnosed with another physical health (95.1%), a mental health problem (49.5%), or both before they received an endometriosis diagnosis. Hence, on average, women in the United States will suffer from endometriosis for 10 years before receiving a proper diagnosis. This bill will expedite the process for women to receive a proper diagnosis for endometriosis and secure treatment to improve fertility and quality of life.
- Endometriosis. According to the U.S. Department of Health and Human Services, National Institutes of Health, endometriosis happens when tissue similar to the lining of the uterus grows outside the uterus. It may affect more than 11% of American women between the ages of 15 and 44, and is common among women in their 30s and 40s. Endometriosis can make it difficult to get pregnant. Endometriosis is diagnosed by pelvic exam, imaging tests, or Laparoscopy (a type of surgery where tissue samples are taken or growths can be seen). Medication can be prescribed to help with the pain caused by endometriosis. Since endometriosis symptoms are nonspecific and can also be present in other diseases diagnosis can be delayed. A 2020 study published in Advances in Therapy found that patients with endometriosis who had longer diagnostic delays had more symptoms and higher utilization and costs compared to those diagnosed earlier. Pre-diagnosis, all-cause healthcare costs were significantly higher among patients with longer diagnostic delays, averaging $21,489, $30,030, and $34,460 among patients with a short, intermediate, and long delay, respectively.
- Related legislation. SB 598 (Skinner) prohibits a health plan or health insurer from requiring a contracted health professional with a total contracting history of at least 36 months, to complete or obtain a prior authorization for any covered health care services if, in the most recent one-year contracted period, the health plan approved or would have approved not less than 90% of the prior authorization requests submitted by the health professional for the class of health care services or treatments subject to prior authorization. SB 598 is scheduled to be heard in this committee on April 12, 2023.
SB 427 (Portantino) prohibits a nongrandfathered health plan contract or health insurance policy from imposing any cost-sharing or utilization review requirements for antiretroviral drugs, devices, or products that are either approved by the federal Food and Drug Administration or recommended by the federal Centers for Disease Control and Prevention for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis. SB 427 is pending in the Senate Health Committee.
AB 931 (Irwin) prohibits a health plan contract or disability insurance policy issued, amended, or renewed on or after January 1, 2025 that provides coverage for physical therapy from requiring prior authorization for the initial 12 treatment visits for physical therapy. AB 931 is scheduled to be heard in the Assembly Health Committee on April 11, 2023.
AB 1288 (Reyes) prohibits a health plan or insurer from subjecting to prior authorization a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance of a substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder. AB 1288 is scheduled to be heard in the Assembly Health Committee on April 25, 2023.
- Support. California Life Sciences writes that endometriosis is a chronic inflammatory disease in which uterine tissue grows in the pelvic region causing severe pain, nausea, fatigue, and even infertility. It affects approximately 10% of reproductive-age women worldwide and domestically. While the exact causes of endometriosis are still an active area of research and no cure has yet to be developed, its symptoms can be effectively managed through early diagnosis and treatments including analgesics, non-steroidal anti-inflammatory drugs, hormonal interventions, and surgical removal of endometriosis growths. Laparoscopic surgery is often preferred among other surgical interventions due to its minimal-invasiveness, minimization of scar tissue, and faster post-operative recovery time. By requiring health plans and insurers to cover laparoscopic surgery for endometriosis, this bill will improve the quality of life for the approximately one million Californians who live with this condition. The American College of OB/GYN’s District IX writes that treatment for endometriosis depends on the extent of the disease, symptoms, and whether a patient wants to have children, as determined by the treating physician. Endometriosis may be treated with medication, surgery, or both. When pain is the primary problem, medication usually is tried first prior to surgery. Regardless of treatment type, a provider and a patient should have access to what is clinically indicated and evidenced based to best treat that individual’s condition, without unnecessary prior authorization requirements which may delay care.
- Opposition. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write in opposition to this along with 23 other health insurance mandate bills. These bills include mandates for health plans and insurers to cover specific services, as well as bills that eliminate cost sharing and limit utilization management, which have similar cost impacts as coverage mandates. Moreover, they will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. State mandates increase costs of coverage – especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates. Benefit mandates that do not promote evidence-based medicine can lead to lower quality care, over- or misutilization of services, and higher costs for treatments that may be ineffective, less safe, or higher cost than other, new or trusted services. California is rightly focused on achieving both universal coverage and cost containment at a time when the national conversation has shifted toward lower costs through less comprehensive options. The California Chamber of Commerce writes employer-based health care coverage is usually one of the largest expenses a business experiences and, while this bill is well-intentioned, it will unintentionally exacerbate health care affordability issues.
- There is limited evidence-based data available to determine how Californians are being impacted by prior authorization policies. There is anecdotal evidence of issues. There are many policy efforts that have been approved by the Legislature that are underway to control high health care costs and encourage the use of health care data exchange with the goal to improve access, quality and affordability for patients. Individual bills should be evaluated in this context. This is one of several bills that are being advanced to address health insurance prior authorization policies.
SUPPORT AND OPPOSITION:
Support: American College of Obstetricians and Gynecologists District IX
California Life Sciences
Oppose: America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
-- END --
Discussed in Hearing
Assembly Standing Committee on Health
Senate Floor
Senate Standing Committee on Health
Bill Author
Bill Co-Author(s):